EDX Medical Group today announced a collaborative agreement with Thermo Fisher Scientific EMEA Ltd. (“Thermo Fisher”), a world leader in supplying life sciences solutions and services.
The collaboration agreement will enable EDX Medical and Thermo Fisher to jointly develop and potentially commercialise a number of clinical-grade assays – including novel and innovative cancer diagnostic solutions. The multi project collaboration will harness Thermo Fisher’s powerful technologies and information translation systems to deliver a number of advanced testing solutions in development at EDX or licensed from partners, including a proprietary assay to enable personalised radiotherapy and a novel chemotherapy toxicity assay focusing on serious adverse events.
The collaboration will leverage combined capabilities to deliver testing solutions being developed at EDX laboratories in Cambridge and Oxford UK, and Ireland.
Professor Sir Chris Evans, founder of EDX Medical, said: “We are delighted to be working closely with such a world leader as Thermo Fisher in order to accelerate the development of our range of exciting new products. These tests will make a real difference to cancer patients. Thermo Fisher’s advanced technologies and knowledge are renowned and coupled with our own scientific team’s focus and expertise, this partnership marks an important milestone in the growth of EDX Medical.”
Dr Mike Hudson, CEO of EDX Medical, said: “This collaboration with Thermo Fisher confirms our capability and ambition to build a significant clinical digital diagnostics business with global scale and impact, cementing both technical and commercial aspects of our laboratory assay business. Our product development pipeline will be enhanced by Thermo Fisher’s knowledge and scalable, class-leading technologies, providing both partners with a means to accelerate the availability of innovative new tests for healthcare professionals and patients around the world.”
Peter Jacobs, Director, EMEA Clinical Business Development, Thermo Fisher Scientific, said: “We are excited at the prospect of working with EDX Medical on a number of their new clinical diagnostic products and are confident that together we will be able to achieve rapid progress and deliver innovative new assays for the global clinical marketplace.”
About Thermo Fisher Scientific
Thermo Fisher Scientific EMEA Ltd is part of Thermo Fisher Scientific Inc. (NYSE: TMO) which is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. www.thermofisherscientific.com
